Myeloid somatic mutation panel testing in myeloproliferative neoplasms.

2021-03-02

Ross, David M

Thomson, Candice

Hamad, Nada

Lane, Steven W

Manos, Kate

Grigg, Andrew P

Guo, Belinda

Erber, Wendy N

Scott, Ashleigh

Viiala, Nick

Chee, Lynette

Latimer, Maya

Tate, Courtney

Grove, Carolyn

Perkins, Andrew C

Blombery, Piers

Myeloproliferative neoplasms

PCR

diagnosis

mutations

prognosis

Journal Article

10.1016/j.pathol.2021.01.003

Myeloproliferative neoplasms are characterised by somatic mutations in pathways that regulate cell proliferation, epigenetic modifications, RNA splicing or DNA repair. Assessment of the mutational profile assists diagnosis and classification, but also aids assessment of prognosis, and may guide the use of emerging targeted therapies. The most practical way to provide information on numerous genetic variants is by using massively parallel sequencing, commonly in the form of disease specific next generation sequencing (NGS) panels. This review summarises the diagnostic and prognostic value of somatic mutation testing in Philadelphia-negative myeloproliferative neoplasms: polycythaemia vera, essential thrombocythaemia, primary myelofibrosis, chronic neutrophilic leukaemia, systemic mastocytosis, and chronic eosinophilic leukaemia. NGS panel testing is increasing in routine practice and promises to improve the accuracy and efficiency of pathological diagnosis and prognosis.

link

Pathology 2021; online first: 2 March

Pathology